Theravance Biopharma (TBPH) Operating Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Operating Expenses data on file, last reported at $27.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 8.85% year-over-year to $27.2 million in Q1 2026; TTM through Mar 2026 was $108.4 million, a 6.08% decrease from a year earlier, with the FY2025 full-year figure at $111.1 million, changed 0.24% from the prior year.
• Operating Expenses for Q1 2026 stood at $27.2 million, up from $25.9 million in the prior quarter.
• Over the last five years, Operating Expenses for TBPH reached as high as $51.7 million in Q1 2022 and fell as low as $21.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $29.8 million across 5 years, with a median of $28.0 million in 2024.
• Across the five-year window, Operating Expenses tumbled 67.68% in 2022 and climbed 17.43% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $32.1 million in 2022, then dropped by 25.8% to $23.8 million in 2023, then increased by 17.43% to $28.0 million in 2024, then fell by 7.42% to $25.9 million in 2025, then grew by 5.03% to $27.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $27.2 million in Q1 2026, $25.9 million in Q4 2025, and $26.4 million in Q3 2025.